Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Roivant Sciences’ SEC documents can feel like wading into clinical trial protocol. Pipeline updates, cash-runway figures, and milestone payments are scattered across hundreds of pages—yet a single sentence can move ROIV’s share price. If you have ever asked, “Where do I find Roivant Sciences insider trading Form 4 transactions before the market reacts?” you know the challenge.
Stock Titan solves it. Our AI instantly parses every submission—whether a dense Roivant Sciences annual report 10-K simplified for pipeline strategy, a fresh Roivant Sciences quarterly earnings report 10-Q filing detailing R&D spend, or an urgent Roivant Sciences 8-K material events explained that discloses trial data. Interactive summaries highlight what matters: Phase III read-outs, collaboration revenue, and liquidity. You can even set real-time alerts for Roivant Sciences Form 4 insider transactions real-time to monitor executive sentiment.
Searching for specifics? Our coverage spans every form investors ask about: 10-K to see cash runway; 10-Q for quarter-over-quarter expense trends; 8-K for FDA designations; the Roivant Sciences proxy statement executive compensation for option grants; and the indispensable Roivant Sciences executive stock transactions Form 4 for ownership changes. Each document comes with plain-English notes—perfect for understanding Roivant Sciences SEC documents with AI and speeding due-diligence. Quickly generate a Roivant Sciences earnings report filing analysis, track disclosure history, or export data for models—no more CTRL-F marathons.
Whether you’re an analyst gauging dilution risk or a healthcare investor timing entry around data catalysts, our platform keeps every question answered and every filing at your fingertips—updated the moment it hits EDGAR.
Roivant Sciences (ROIV) Form 4, filed 1 Aug 2025, discloses a large equity grant to President & Vant Chair Frank Torti. On 30 Jul 2025 he received (i) 1,836,547 time-based RSUs that vest 20 % after one year and quarterly thereafter, and (ii) 11,900,000 performance-based PSUs split into six price-hurdle tranches ($15–$30). Each tranche vests only after both a share-price test (30-day VWAP before 26 Jul 2029) and one additional year of service, followed by a two-year holding lock-up. The award was granted at $0 cost; no open-market buying occurred.
Post-grant, Torti’s beneficial ownership rises to 13,736,547 common shares, all held directly. While the structure tightly links vesting to long-term price performance, full issuance would add material dilution if all hurdles are met.
Roivant Sciences Ltd. (ROIV) – Form 4 filing: President & Immunovant CEO Eric Venker reported an equity award on 30 Jul 2025. The grant comprises 198,413 restricted stock units (RSUs) for common shares at a cost basis of $0. Vesting begins 20 May 2025, with 25 % vesting on the first anniversary and the balance in 12 equal quarterly tranches, contingent upon continued service.
Post-grant, Venker’s direct beneficial ownership rises to 1,660,636 common shares. The filing contains no open-market purchases or sales; therefore, it signals executive retention rather than a valuation view. The transaction represents routine equity compensation and has minimal immediate dilution or cash-flow impact for shareholders.
Roivant Sciences (ROIV) – Form 4 filing (30 Jul 2025)
CFO Richard Pulik reported an automatic disposition of 1,919 common shares on 28 Jul 2025 at an implied price of $11.35. The transaction is coded “F”, indicating the issuer withheld shares to cover taxes due upon the vesting of previously granted restricted stock units (RSUs); no open-market sale occurred. After the net-settlement, Pulik retains 397,553 shares, so the shares surrendered equal roughly 0.5 % of his post-transaction holdings. Because the activity is tax-related and immaterial to overall ownership, it is typically viewed as routine rather than a directional signal on the company’s prospects.
Roivant Sciences (ROIV) – Form 3. President & Vant Chair Frank Torti has filed his initial beneficial-ownership report covering 10.27 million common shares underlying stock options. Exercise prices range from $3.85 to $13.07 with expiry dates between 2028-2032. The largest tranche is 6.03 million options at $3.85 that vest 25% on 20-Apr-2023 and monthly thereafter; all other grants are already fully vested. No non-derivative share holdings were disclosed. The filing confirms Torti’s officer status and records his equity incentives for Section 16 compliance.
FAQ
What is the current stock price of Roivant Sciences (ROIV)?
What is the market cap of Roivant Sciences (ROIV)?
